Peanut Allergy Targeted By DBV Technologies As It Raises $55 Million In Second Euro Biotech IPO This Year
This article was originally published in The Pink Sheet Daily
France's DBV Technologies lists on NYSE Euronext in Paris and targets peanut and other food allergies for the first clinical studies of its epicutaneous patches as allergy desensitization therapies.
You may also be interested in...
The French biotech will set out its stall first in the U.S., where peanut allergy is a major concern, and plans to tackle the life-threatening condition with its transdermal patch without relying on local partners.
Nanotechnology which amplifies the antitumor effects of radiotherapy is being developed by French company Nanobiotix, which has just completed an IPO on NYSE Euronext in Paris, following investment by the general public in France via citizen's funds.
French drug delivery company, Adocia, raises $33 million to develop new formulations of therapeutic proteins for wound healing, diabetes